Immix Biopharma (IMMX) IPO Opens Flat

Today's IPO for Immix Biopharma, Inc. (Nasdaq: IMMX) opened for trading at $5 after pricing 4,200,000 shares of its common stock at a public offering price of $5.00 per share.

ThinkEquity is acting as the sole book-running manager for the offering.

ImmixBio is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-SpecificTM Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and immuno-dysregulation. In addition to oncology, our pipeline includes Tissue-Specific BiologicTM candidates to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Learn more at www.immixbio.com.

You May Also Be Interested In